Robuta

https://www.preprints.org/manuscript/201812.0315
Gastrointestinal stromal tumors are the mostly seen mesenchymal tumors of the gastrointestinal system. This rare tumor in duodenum is seen 5%. The diagnosis...
stromal tumorgastrointestinalduodenumpreprintsorg
https://pubmed.ncbi.nlm.nih.gov/31730471/
Of the 18 cases analyzed and our present case, metastasis typically involved the cerebrum with only one in infratentorial elements. The tumors in seven of the...
stromal tumorcase presentationgastrointestinalintracranialmetastasis
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1398055/full
Introduction: Regorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) indicated for the treatment of various tumor types, including metastatic ...
stromal tumorfrontiersregorafenibrelatederythrocytosis
https://pubmed.ncbi.nlm.nih.gov/26527782/
Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations...
high riskstromal tumoradjuvantimatinibgi
https://www.goodrx.com/conditions/gist
stromal tumorgastrointestinalgistgoodrx
https://www.pharmaceutical-technology.com/data-insights/gastrointestinal-stromal-tumor-gist-drugs-in-development/
GlobalData tracks 65 drugs in development for Gastrointestinal Stromal Tumor (GIST) by 55 companies/universities/institutes. The top development phase for...
stromal tumorgastrointestinalgistdrugsdevelopment
https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging.html
Know the signs and symptoms of gastrointestinal stromal tumors. Find out how GIST is tested for, diagnosed, and staged.
stromal tumorearly detectionamerican cancergastrointestinaldiagnosis
https://www.pharmaceutical-technology.com/data-insights/likelihood-of-approval-gastrointestinal-stromal-tumor-gist/
Gastrointestinal Stromal Tumor (GIST) disease is an indication for drug development with over 70 pipeline drugs currently active according to GlobalData.
stromal tumorgastrointestinalgistdrugslikelihood